GMP production of [18F]FDOPA and issues concerning its quality analyses as in USP "fluorodopa F 18 Injection"

Annals of Nuclear Medicine

Volumn 25, Issue 5, 2011, Pages 309-316

  Kao, Chih Hao K ^a,b   Hsu, Wen Lin ^a,c   Xie, Heng Li ^a   Lin, Ming Chi ^a   Lan, Wen Chun ^a   Chao, Hao Yu ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

Author keywords

6 18F Fluoro L DOPA; Fluorodopa F 18 Injection; PET drug GMP; United States Pharmacopeia

Indexed keywords

6 FLUORODOPA F 18; ORGANOTIN COMPOUND; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ARTICLE; ASEPSIS; CERTIFICATION; DRUG MANUFACTURE; DRUG PURITY; DRUG QUALITY; DRUG STABILITY; DRUG SYNTHESIS; ELECTROPHILICITY; GOOD MANUFACTURING PRACTICE; GOVERNMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; STANDARD; SUBSTITUTION REACTION; ECONOMICS; EQUIPMENT; INJECTION; MATERIALS; MICROBIOLOGY; NON PROFIT ORGANIZATION; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; UNITED STATES;

DIHYDROXYPHENYLALANINE; EQUIPMENT CONTAMINATION; INJECTIONS; MANUFACTURED MATERIALS; MICROBIOLOGY; ORGANIZATIONS, NONPROFIT; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; UNITED STATES;

EID: 80052327810     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0463-x     Document Type: Article

References (23)

1. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol. 2004;11:5-12. (Pubitemid 38174915)
2. Thobois S, Guillouet S, Broussolle E. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease. Neurophysiol Clin. 2001;31:321-40. (Pubitemid 33054611)
3. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137-8. (Pubitemid 14235666)
4. Minn H, Kauhanen S, Seppänen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. J Nucl Med. 2009;50:1915-8.
5. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008;26:1489-95.
6. Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J Nucl Med. 2004;45: 1161-7. (Pubitemid 47611661)
7. Lemaire C, Damhaut P, Plenevaux A, Comar D. Enantioselective synthesis of 6-[fluorine-18]-fluoro-L-dopa from no-carrier-added fluorine-18-fluoride. J Nucl Med. 1994;35:1996-2002. (Pubitemid 24376619)
8. Adam MJ, Ruth TJ, Grierson JR, Abeysekera B, Pate BD. Routine synthesis of L-[18F]6-fluorodopa with fluorine-18 acetyl hypofluorite. J Nucl Med. 1986;27:1462-6. (Pubitemid 17028569)
9. de Vries EFJ, Luurtsemaa G, Brüssermannb M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[18F]fuoro-L-DOPA. Appl Radiat Isot. 1999;51:389-94. (Pubitemid 29359297)
10. Chang CW, Wang HE, Lin HM, Chtsai CS, Chen JB, Liu RS. Robotic synthesis of 6-[18F]fluoro-L-dopa. Nucl Med Commun. 2000;21:799-802.
11. Food and Drug Administration Center for Drug Evaluation and Research. Guidance: PET Drugs-Current Good Manufacturing Practice (CGMP). In: Guidances (Drugs)/Current Good Manufacturing Practices (CGMPs). United States Department of Health and Human Services. 2005. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070306.pdf. Accessed 29 July 2010.
12. European Commission Enterprise and Industry. Volume 4: EU guidelines to good manufacturing practice: medicinal products for human and veterinary use; Annex 3: Manufacture of Radiopharmaceuticals. In: EudraLex, The Rules Governing Medicinal Products in the European Union. European Commission. 2008. http://ec.europa.eu/health/files/eudralex/vol-4/pdfs-en/anx03-en.pdf. Accessed 6 Aug 2010.
13. Pharmaceutical Inspection Cooperation Scheme. Annex 3: Manufacture of radiopharmaceuticals In: PE 009-9 (Annexes) Guide to good manufacturing practice for medicinal products, Annexes. Pharmaceutical Inspection Convention. 2009. http://www.picscheme.org/publication.php?id=4. Accessed 29 July 2010.
14. United States Pharmacopeial Convention. Monographs: Fluorodopa F 18 Injection. In: USP31/NF26, vol 2. 2008. p. 2193-4.
15. Pharmaceutical Inspection Cooperation Scheme. Annex 1: Manufacture of sterile medicinal products. In: PE 009-9 (Annexes) Guide to good manufacturing practice for medicinal products, Annexes. Pharmaceutical Inspection Convention. 2009. http://www.picscheme.org/publication.php?id=4. Accessed 29 July 2010.
16. United States Pharmacopeial Convention. Reagents, indicators, and solutions: chromatographic reagents. In: USP31/NF26, vol 1. 2008. p. 810-2.
17. Boué J, Audebert R, Quivoron C. Direct resolution of alphaamino acid enantiomers by ligand exchange: stereoselection mechanism on silica packings coated with a chiral polymer. J Chromatogr. 1981;204:185-93. (Pubitemid 11128101)
18. Lemaire C, Guillaume M, Cantineau R, Christiaens L. No-carrieradded regioselective preparation of 6-[18F]fluoro-L-dopa. J Nucl Med. 1990;31:1247-51.
19. Ishiwata K, Ido T, Vaalburg W. Increased amount of D-enantiomer dependent on alkaline concentration in the synthesis of L-[methyl-11C]methionine. Appl Radiat Isot. 1988;39:311-4.
20. Schlauch M, Volk FJ, Fondekar KP, Wede J, Frahm AW. Enantiomeric and diastereomeric high-performance liquid chromatographic separation of cyclic beta-substituted alpha-amino acids on a copper(II)-D-penicillamine chiral stationary phase. J Chromatogr. 2000;897:145-52.
21. Pfeffer M, Gelbe B, Hampe P, Steinberg B, Walenciak-Reddel E, Woicke B, et al. Sensitive fluorescence labeling for analysis of organotin compounds with morin. Fresenius J Anal Chem. 1992;342:839-45.
22. Dean JH, Murray MJ. Toxic responses of the immune system. In: Amdur MO, Doull J, Klaassen CD, editors. Casarett and Doull's toxicology: the basic science of poisons. 4th ed. New York: Pergamon Press; 1991. p. 282-333.
23. European Union. 2009/425/EC: Commission Decision of 28 May 2009 amending Council Directive 76/769/EEC as regards restrictions on the marketing and use of organostannic compounds for the purpose of adapting its Annex I to technical progress. In: Official Journal of the European Union, 4 June 2009; vol 4, L138/11-13. http://eur-lex.europa.en/LexUriServ/LexUriServ.do?uri=OJ:L:2009:138: 0011:0013:EN:PDF. Accessed 8 Nov 2010.